Ajay Verma - 01 Dec 2021 Form 4 Insider Report for YUMANITY THERAPEUTICS, INC. (KANT)

Role
EVP, Head of R&D
Signature
/s/ Marie Epstein, Attorney-in-Fact
Issuer symbol
KANT
Transactions as of
01 Dec 2021
Net transactions value
$0
Form type
4
Filing time
03 Dec 2021, 15:15:58 UTC
Previous filing
15 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KA Common Stock Award $0 +30,000 $0.000000 30,000 01 Dec 2021 Direct F1
holding KA Common Stock 200 01 Dec 2021 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock award granted under the Yumanity Therapeutics, Inc. Amended and Restated 2018 Stock Option and Grant Plan. Fifty percent of the shares subject to the award will vest six months after the grant date and fifty percent will vest twelve months after the grant date, provided that the award recipient continues to have a service relationship with the Company at such time.